12 June 2018 - Sunovion seeks approval for apomorphine sublingual film for the on-demand treatment of OFF episodes associated with Parkinson’s disease.

Sunovion Pharmaceuticals announced today that the U.S. FDA has accepted the new drug application for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease. 

The expected action date by the FDA under the Prescription Drug User Fee Act is 29 January 2019.

Read Sunovion Pharmaceuticals press release